Document:

Exhibit 4.3

Consent of Independent Registered
Public Accounting Firm

We have issued our
report dated March 31, 2020, with respect to the financial statement of SmartTrust 471 contained in Amendment No. 1 to the Registration
Statement on Form S-6 (File No. 333-235524) and related Prospectus. We consent to the use of the aforementioned report in the Registration
Statement and Prospectus, and to the use of our name as it appears under the caption “Independent Registered Public Accounting
Firm”.

 

/s/ Grant
Thornton LLP

 

Chicago, Illinois

March 31, 2020Exhibit 4.11

 

Bioceres
Crop Solutiuons Corp.

 

Shareholders’
Agreement

 

THIS
SHAREHOLDERS’ AGREEMENT (this “Agreement”) is made as of March 14, 2019, by and among Bioceres
Crop Solutions Corp., a Cayman Islands exempted company (the “Company”), Bioceres LLC (“Bioceres”)
and the shareholders set forth on Schedule A attached hereto (collectively, the “Shareholders”).
The number of the Company’s ordinary shares (the “Ordinary Shares”) held by each Shareholder as
of February 21, 2019 is set forth on Schedule A hereto.

 

AGREEMENT

 

WHEREAS,
as of the Closing Date of the Business Combination, the Shareholders collectively own the Initial Share Ownership Amount (as defined
below);

 

WHEREAS,
parties hereto wish to enter into this Agreement for the purposes of regulating the business, affairs and management of the Company
as from the date hereof;

 

NOW
THEREFORE, in consideration of the mutual promises set forth herein and for other good and valuable consideration, the receipt
and sufficiency of which is hereby expressly acknowledged, the parties hereto agree as follows:

 

1.             
Certain Definitions.

 

In
this Agreement:

 

“Affiliate”
shall mean with respect to any person, a person that directly, or indirectly through one or more intermediaries, controls, is
controlled by, or is under common control with, such person, and, in the case of an individual, includes any relative or spouse
of such person. The term “control” means the possession, directly or indirectly, of the power to direct or
cause the direction of the management and policies of a person, whether through the ownership of voting securities by contract
or otherwise. The term “person” means an individual, a partnership, a corporation, an association, a joint
stock company, a trust, a joint venture, a limited liability company, an unincorporated organization or a governmental entity
or any department, agency or political subdivision thereof.

 

“Articles”
shall mean the Company’s amended and restated memorandum and articles of association.

 

“Business
Combination” shall mean the transactions contemplated by the Exchange Agreement.

 

“Closing
Date” shall mean the closing date of the Business Combination under the Exchange Agreement.

 

“Exchange
Agreement” shall mean the share exchange agreement, dated as of November 8, 2018, as may be amended from time to
time, by and among the Company, Joseph J. Schena, solely in his capacity as representative of the holders of the Company’s
ordinary shares, and Bioceres, Inc.

 

      

     

    

 

“Initial
Share Ownership Amount” shall mean 2,012,500 Ordinary Shares.

 

2.              Representation
on the Board.

 

(a)              
For so long as the Shareholders collectively continue to beneficially own, directly or indirectly, at least twenty-five percent
(25%) of the Initial Share Ownership Amount (the “Minimum Shares”), the Shareholders shall be entitled
to nominate one (1) Director (a “UAC Director”) to the Board of Directors of the Company (the “Board”)
at every annual meeting of the Company. Bioceres hereby agrees to vote in favor of the appointment of such UAC Director.

 

(b)              
On the Closing Date, Bioceres shall cause two (2) UAC Directors that are identified and designated by the Shareholders to be appointed
to the Board; provided, that, one (1) such UAC Director shall immediately resign. If, as a result of death, disability, retirement,
resignation, removal or otherwise, the remaining UAC Director is unable to serve on the Board, the Shareholders shall be entitled
to designate a replacement UAC Director to serve on the Board. In such event, Bioceres and the Company shall take any and all
necessary actions to ensure the election or appointment, as applicable, of such designated UAC Director to the Board.

 

(c)              
As of immediately following the Closing Date, after giving effect to the appointment of two (2) UAC Directors, one of whom will
immediately resign, the Board will be comprised of seven (7) members.

 

(d)              
The UAC Director shall be entitled to the same rights, capacities, entitlements, compensation (if she or he serves as an independent
director), indemnification and insurance in connection with his or her role as a director as other members of the Board, and shall
be entitled to reimbursement for all reasonable documented, out-of-pocket expenses incurred in attending meetings of the Board
or any committees thereof, to the same extent as other members of the Board. The Company shall, upon the appointment of the UAC
Directors and resignation of one UAC Director, enter into indemnification agreement with the remaining UAC Director in the same
form as applicable to other members of the Board with such UAC Directors.

 

(e)              
In addition, the UAC Director shall be entitled to coverage under the Company’s directors’ and officers’ liability
insurance with the same coverage as, and containing terms and conditions no less favorable than, those available to the other
members of the Board; which coverage shall be effective upon his or her appointment to the Board and, for the avoidance of doubt,
which shall continue in accordance with its terms notwithstanding the termination of this Agreement.

 

(f)               
The UAC Director shall be entitled to serve on the audit committee of the Board; provided, however, that notwithstanding the foregoing,
such UAC Director shall not be entitled to serve on the audit committee of the Board if, as determined in good faith by a majority
of the Board (based upon the advice of outside legal counsel), such service on the audit committee would violate any applicable
laws or applicable listing rules.

 

      

     

    

 

(g)              
The Company and the Board shall ensure, to the extent lawful, at all times that the Articles and corporate governance policies
and guidelines of the Company are not at any time inconsistent with this Section 2.

 

(h)              
The Shareholders acknowledge and agree that all Directors (including any UAC Director) shall be subject to the Company’s
code of business conduct and ethics.

 

3.                 
Removal of UAC Directors. Bioceres and each Shareholder also agree to vote, or cause to be voted, all Ordinary Shares owned
by them, or over which they have voting control, from time to time and at all times, in whatever manner as shall be necessary
to ensure that the UAC Director appointed pursuant to Sections 2(a) of this Agreement may not be removed from office unless
such removal is for cause and approved pursuant to Section 5(c) of the Articles.

 

4.                 
Corporate Opportunities. The parties hereto agree that the Shareholders and their Affiliates (other than the Company and
its subsidiaries) shall be able to engage in a competitive business and renounce certain corporate opportunities offered to such
Shareholders or their Affiliates (other than the Company and its subsidiaries), so long as such corporate opportunities are not
expressly offered to such Shareholders in their capacities as a UAC Director; provided, however, that to the extent
that a Shareholder acquires knowledge of a potential transaction or matter that may be a corporate opportunity for the Company,
as a result of acting in his or her capacity as a UAC Director, then such Shareholder shall present such opportunity to the Company
and may not pursue such opportunity for itself, or direct such opportunity to another person, unless the Company has declined
to pursue such opportunity.

 

5.                 
General Covenants of the Company. The Company agrees to use its best efforts, within the requirements of applicable law,
to ensure that the rights granted under this Agreement are effective and that the parties enjoy the benefits of this Agreement.
Such actions include, without limitation, the use of the Company’s best efforts to cause the nomination and appointment
of the UAC Directors as provided in this Agreement.

 

6.                 
Additional Shares. In the event that subsequent to the date of this Agreement any shares or other securities are issued
on, or in exchange for, any of the Ordinary Shares by reason of any stock dividend, stock split, consolidation of shares, reclassification
or consolidation involving the Company, such shares or securities shall be deemed to be Ordinary Shares for purposes of this Agreement.

 

7.                 
Termination. This Agreement shall terminate on the date the number of Ordinary Shares beneficially owned by the Shareholders is
less than the number of Minimum Shares.

 

8.                 
Confidentiality. The UAC Directors shall be required to preserve the confidentiality of, and not disclose, any non-public
information of the Company or any of its subsidiaries, including discussions or matters considered in meetings of the Board or
any committees thereof, to any third party.

 

      

     

    

 

9.                 
Miscellaneous.

 

(a)       Notices.
All notices, requests, demands, consents, instructions or other communications required or permitted hereunder shall be in writing
and faxed, e-mailed, mailed, or delivered to each party as follows: (x) if to a Shareholder, at such Shareholder’s address,
facsimile number or e-mail address set forth in the Company’s records, or at such other address, facsimile number or e-mail
address as such Shareholder shall have furnished the Company in writing, or (y) if to the Company, at the address set forth on
the signature pages hereto, or at such other address or facsimile number as the Company shall have furnished to the Shareholders
in writing. All such notices and communications will be deemed effectively given the earlier of (i) when received, (ii) when delivered
personally, (iii) one business day after being delivered by facsimile or e-mail (with receipt of appropriate confirmation), (iv)
one business day after being deposited with an overnight courier service of recognized standing or (v) five days after being deposited
in the mail, first class with postage prepaid. With respect to any notice given by the Company under any provision of any applicable
laws or the Company’s Articles, each Shareholder agrees that such notice may be given by facsimile or by electronic mail.

 

(b)       Successors
and Assigns. The provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns,
heirs, executors and administrators of the parties hereto.

 

(c)       Governing
Law. This Agreement shall be governed in all respects by the internal laws of the State of New York.

 

(d)       Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless
otherwise provided, refer to sections and paragraphs hereof and exhibits attached hereto.

 

(e)       Further
Assurances. Each party hereto agrees to execute and deliver, by the proper exercise of its corporate, limited liability company,
partnership or other powers, all such other and additional instruments and documents and so all such other acts and things as
may be necessary to more fully effectuate this Agreement.

 

(f)       Entire
Agreement. This Agreement constitutes the full and entire understanding and agreement among the parties with regard to the
subjects hereof. No party hereto shall be liable or bound to any other party in any manner with regard to the subjects hereof
or thereof by any warranties, representations or covenants except as specifically set forth herein.

 

(g)       Amendment.
Neither this Agreement nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument
referencing this Agreement and signed by (i) the Company, (ii) Bioceres and (iii) the Shareholders holding at least the majority
of Ordinary Shares held by the Shareholders. Notwithstanding the above, any amendment to this Agreement that adversely alters,
changes or affects the rights, preferences or privileges of any Shareholder shall require the written consent of such Shareholder.

 

(h)       No
Waiver. The failure or delay by a party to enforce any provision of this Agreement will not in any way be construed as a waiver
of any such provision or prevent that party from thereafter enforcing any other provision of this Agreement. The rights granted
parties hereunder are cumulative and will not constitute a waiver of any party’s right to assert any other legal remedy
available to it.

 

      

     

    

 

(i)       Severability.
If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or
void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement,
and such court will replace such illegal, void or unenforceable provision of this Agreement with a valid and enforceable provision
that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable
provision. The balance of this Agreement shall be enforceable in accordance with its terms.

 

(j)       Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together
will constitute one and the same agreement. Facsimile copies of signed signature pages will be deemed binding originals.

 

[Remainder
of Page Intentionally Blank]

 

      

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set forth above.

 

	 	Bioceres
    Crop Solutions Corp.
	 	 	 
	 	By:  	/s/
    Federico Trucco
	 	 	Name:
    Federico Trucco
	 	 	Title:
    Chief Executive Officer
	 	 
	 	Address:
	 	 	 
	 	Ocampo
    210 bis
	 	Predio
    CCT, Rosario, Sta. Fe
	 	Argentina

 

[Signature
Page to Shareholders’ Agreement] 

 

      

     

    

 

	 	Bioceres
    LLC
	 	 
	 	By:  	/s/
    Federico Trucco
	 	 	Name:
    Federico Trucco
	 	 	Title:
    Chief Executive Officer
	 	 
	 	Address:
	 	 
	 	Ocampo
    210 bis
	 	Predio
    CCT, Rosario, Sta. Fe
	 	Argentina

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	SHAREHOLDERS:
	 	 
	 	Kyle
    P. Bransfield
	 	 
	 	/s/
    Kyle P. Bransfield
	 	Signature
	 	 
	 	Address:
	 	 
	 	444
    Madison Ave, Floor 34
	 	New
    York, NY 10022

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Gerald
    W. Haddock
	 	 
	 	/s/
    Gerald W. Haddock
	 	Signature
	 	 
	 	Address:
	 	 
	 	500
    Main St., Suite 1015
	 	Ft.
    Worth, Texas 76102

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Daniel
    W. Fink
	 	 
	 	/s/
    Daniel W. Fink
	 	Signature
	 	 
	 	Address:
	 	 
	 	1733
    Majestic Drive, Suite 103
	 	Lafayette,
    CO 80026

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Joseph
    J. Schena
	 	 
	 	/s/
    Joseph J. Schena
	 	Signature
	 	 
	 	Address:
	 	 
	 	545
    Sanctuary Drive, B505
	 	Longboat
    Key, FL 34228

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Union
    Group International Holdings Limited
	 	 
	 	By:  	/s/
    Juan Sartori
	 	 	Name:
    Juan Sartori
	 	 	Title:
    Chairman
	 	 
	 	Address:
	 	 
	 	Plaza
    Independencia 737
	 	Montevideo,
    Uruguay

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Union
    Acquisition Associates, LLC
	 	 
	 	By:  	/s/
    Kyle P. Bransfield
	 	 	Name:
    Kyle P. Bransfield
	 	 	Title:
    Member
	 	 	 
	 	Address:
	 	 
	 	444
    Madison Ave, Floor 34
	 	New
    York, NY 10022

 

[Signature
Page to Shareholders’ Agreement]

 

     

     

    

 

	 	PENSCO
    Trust Company
	 	 
	 	By:  	/s/
    Kyle P. Bransfield
	 	 	Name:
    Kyle P. Bransfield
	 	 	Title:
    Authorized Signatory
	 	 	 
	 	Address:
	 	 
	 	444
    Madison Ave, Floor 34
	 	New
    York, NY 10022

 

[Signature
Page to Shareholders’ Agreement]

 

     

     

    

 

	 	Jim Manley
	 	 
	 	/s/ Jim
    Manley
	 	Signature
	 	 
	 	Address:
	 	 
	 	c/o Atlantic Pacific Capitol Inc.
	 	444 Madison Avenue, 34th Floor
	 	New York, NY 10022

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	William B. Buchanan, Jr.
	 	 
	 	/s/ William
    B. Buchanan, Jr.
	 	Signature
	 	 
	 	Address:
	 	 
	 	8 Smith Ridge Lane
	 	New Canaan, CT 06840

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Michael Fontaine
	 	 
	 	/s/ Michael
    Fontaine
	 	Signature
	 	 
	 	Address:
	 	 
	 	123 Washington Street, 42G
	 	New York, New York 10006

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Scott A. Katzmann
	 	 
	 	/s/ Scott
    A. Katzmann
	 	Signature
	 	 
	 	Address:
	 	 
	 	53 Westgate Blvd.
	 	Plandome, NY 11030

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Ladenburg Thalmann & Co. Inc.
	 	 
	                                                                      	By:	/s/
    Ladenburg Thalmann & Co. Inc.
	 	 	Name: Steven Kaplan
	 	 	Title: Head of Capital Markets
	 	 
	 	Address:
	 	 
	 	277 Park Avenue, 26th Floor
	 	New York, NY 10172

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Joseph Anthony Lasala
	 	 
	 	/s/ Joseph
    Anthony Lasala
	 	Signature
	 	 
	 	Address:
	 	 
	 	Joe Lasala
	 	2012 Byrne Hall
	 	Hanover, NH 03755

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Harris Lvdon
	 	 
	 	/s/ Harris
    Lvdon
	 	Signature
	 	 
	 	Address:
	 	 
	 	17 White Street, 2B
	 	New York, New York 10013

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Graham A. Powis
	 	 
	 	/s/ Graham
    A. Powis
	 	Signature
	 	 
	 	Address:
	 	 
	 	10 Francine Dr.
	 	Greenwich, CT 06830

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

	 	Patrick A. Sturgeon
	 	 
	 	/s/ Patrick
    A. Sturgeon
	 	Signature
	 	 
	 	Address:
	 	 
	 	509 Madison Avenue, Ninth Floor
	 	New York, NY 10022

 

[Signature
Page to Shareholders’ Agreement]

 

      

     

    

 

Schedule
A

 

Number
of Ordinary Shares Held by Each Shareholder

 

 

	KYLE
    P BRANSFIELD	 	 	13,101	 
	WILLIAM
    B BUCHANAN JR	 	 	26,760	 
	DANIEL
    W FINK	 	 	25,000	 
	MICHAEL
    FONTAINE	 	 	1,965	 
	GERALD
    W HADDOCK	 	 	25,000	 
	SCOTT
    A KATZMANN	 	 	26,758	 
	LADENBURG
    THALMANN & CO INC	 	 	100,222	 
	JOSEPH
    ANTHONY LASALA	 	 	3,930	 
	HARRIS
    LYDON	 	 	26,758	 
	JIM
    MANLEY	 	 	248,918	 
	PENSCO
    TRUST COMPANY	 	 	75,000	 
	GRAHAM
    A POWIS	 	 	4,225	 
	JOSEPH
    J SCHENA	 	 	25,000	 
	PATRICK
    A STURGEON	 	 	9,826	 
	UNION
    GROUP INTERNATIONAL	 	 	1,619,954	 
	UNION
    ACQUISITION ASSOCIATES LLC	 	 	642,583	 

 

      

     

    

 

Schedule
A

 

Number
of Ordinary Shares Held by Each Shareholder

 

 

	KYLE
    P BRANSFIELD	 	 	13,101	 
	WILLIAM
    B BUCHANAN JR	 	 	26,760	 
	DANIEL
    W FINK	 	 	25,000	 
	MICHAEL
    FONTAINE	 	 	1,965	 
	GERALD
    W HADDOCK	 	 	25,000	 
	SCOTT
    A KATZMANN	 	 	26,758	 
	LADENBURG
    THALMANN & CO INC	 	 	100,222	 
	JOSEPH
    ANTHONY LASALA	 	 	3,930	 
	HARRIS
    LYDON	 	 	26,758	 
	JIM
    MANLEY	 	 	248,918	 
	PENSCO
    TRUST COMPANY	 	 	75,000	 
	GRAHAM
    A POWIS	 	 	4,225	 
	JOSEPH
    J SCHENA	 	 	25,000	 
	PATRICK
    A STURGEON	 	 	9,826	 
	UNION
    GROUP INTERNATIONAL HOLDINGS LIMITED	 	 	1,619,954	 
	UNION
    ACQUISITION ASSOCIATES LLC	 	 	642,583

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]